MCRI to build on CyGenics' stem cell scaffold
Friday, 13 August, 2004
Stem cell company CyGenics (ASX: CYN) will collaborate with the Murdoch Children's Research Institute to perform clinical trials demonstrating that stem cells expanded from umbilical cord blood using CyGenics subsidiary Cytomatrix's proprietary cell growth scaffold retain full functionality and effectiveness.
Cytomatrix will transfer the technology, which has been shown to work for the expansion of human bone marrow stem cells, cord blood stem cells and peripheral blood stem cells, to researchers working at the MCRI.
A grant of AUD$50,000 has been awarded to the company through the Federal Government's International Science Linkages Program to support the trials.
Genetic cause found for rare neurological disease
The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare movement...
Creating self-assembling capsules for drug delivery
Scientists have created nanosized capsules that could be used to deliver drugs and messenger RNA...
Simulated microgravity affects sleep, physiological rhythms
The simulated effects of microgravity significantly affect rhythmicity and sleep in humans, which...
